Drawing for ORIEN ATLAS

USPTO serial 88082824

ORIEN ATLAS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
MAYES, LAURIE ANN
Law office
TMEG LAW OFFICE 101 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ORIEN ATLAS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Corey K. Cho

COREY K. CHO SALIWANCHIK, LLOYD & EISENSCHENK, P.A3107 S.W. WILLISTON ROADGAINESVILLE, FL 32608UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009Computer architecture and software for use in the fields of biomedical research and healthcare informatics, namely, customized architecture and software designed for use by healthcare providers and biopharmaceutical companies to integrate, analyze and share clinical, biomedical, clinical trial, and laboratory research data and healthcare information to enhance discovery, development and commercialization of pharmaceuticals and improve the delivery of personalized healthcare; Computer architecture and software for data warehousing for use in the fields of clinical patient care, namely, to identify and assign patient to a similar cohort of patients for the purpose of prediction and recommending options available to such patients based on the outcomes observed from patients in the cohortACTIVE—
042Design and development of computer architecture and software for providing a data platform in the fields of biomedical research and healthcare informatics; providing an online computer database in the fields of biopharmaceutical and healthcare informatics relating to data warehousing, data mining, data encryption, data mapping and electronic data storage; Consulting, advisory and information services in the field of use of data warehousing, electronic data storage and design and development of data warehousing systems relating to clinical and operational comparative patient, syndrome, and healthcare systems performance data for discovery, development and commercialization of pharmaceuticals; data warehousing in the fields of biopharmaceuticals and healthcare informatics, namely, use of a database to identify a population of patients who are most similar to a single patient being seen at the point of care in order to assist and enable prediction of the patient's needs and potential outcomes by assigning the single patient to the similar patient cohort identified in the data warehouse; consulting services in the fields of biopharmaceuticals and healthcare informatics relating to data warehousing, data mining, data encryption, data mapping and electronic data storage; scientific research and development in the fields of biopharmaceuticals and healthcare informatics via a database featuring inputting and collection of data and information used for discovery, developments and commercialization of pharmaceuticals; data collection for research purposes, namely, collecting clinical data in the field of oncology; medical research services in the field of cancerACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jul 12, 2019MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 12, 2019ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Dec 12, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 12, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 12, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 4, 2018DOCKASSIGNED TO EXAMINER—
Aug 26, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 21, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance